Literature DB >> 21658939

Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways.

Voralak Vichapat1, Cheryl Gillett, Ian S Fentiman, Andrew Tutt, Lars Holmberg, Margreet Lüchtenborg.   

Abstract

Although many studies show an increased risk of metachronous contralateral breast cancer (CBC) in women with a positive family history and young age at diagnosis of the initial breast cancer, the aetiological pathways are still enigmatic. In a cohort of 8478 primary breast cancer patients diagnosed between 1975 and 2006, 558 cases of metachronous CBC were identified. Using multivariate Cox proportional hazards models, we analysed risk factors assessed at the time of the first primary tumour, including patient demographics, tumour characteristics and treatment among 4681 breast cancer patients for whom data on key variables were available. The analysis was performed separately in patients who developed CBC without and with prior recurrence(s). Risk of CBC without prior recurrent disease was increased by a positive family history [adjusted relative risk (RR) 2.8 (95% confidence interval (CI) 1.4-5.5)]; and decreased by endocrine treatment [RR 0.6 (95% CI 0.4-1.0)]. We found an increased risk of CBC with prior recurrent disease with younger age [RR 1.2 (95% CI 1.4-3.0)]; positive family history [RR 2.1 (95%CI 0.8-5.0)]; and extensive lymph node involvement [RR 2.0 (95% CI 1.2-3.6)]. Our results suggest that nodal status of the primary tumour may be as important a risk factor as family history or age, which indicates a high susceptibility to breast cancer or an impaired host defence mechanism. It may also imply that some CBCs are metastases from the first primary tumour, particularly in patients who present with recurrent disease before CBC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21658939     DOI: 10.1016/j.ejca.2011.05.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.

Authors:  Julia Prater; Fabio Valeri; Dimitri Korol; Sabine Rohrmann; Silvia Dehler
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-23       Impact factor: 4.553

2.  Long-term results after 12-year follow-up of patients treated with whole-breast and boost irradiation after breast-conserving surgery.

Authors:  Shigeo Takahashi; Yuji Murakami; Nobuki Imano; Yuko Kaneyasu; Yoshiko Doi; Masahiro Kenjo; Tomoki Kimura; Takayuki Kadoya; Koji Arihiro; Tsuyoshi Kataoka; Morihito Okada; Yasushi Nagata
Journal:  Jpn J Radiol       Date:  2016-06-17       Impact factor: 2.374

3.  Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study.

Authors:  Maria E C Sandberg; Per Hall; Mikael Hartman; Anna L V Johansson; Sandra Eloranta; Alexander Ploner; Kamila Czene
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

4.  ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.

Authors:  Jian Pan; Li-Chao Sun; Yan-Fang Tao; Zhuan Zhou; Xiao-Li Du; Liang Peng; Xing Feng; Jian Wang; Yi-Ping Li; Ling Liu; Shui-Yan Wu; Yan-Lan Zhang; Shao-Yan Hu; Wen-Li Zhao; Xue-Ming Zhu; Guo-Liang Lou; Jian Ni
Journal:  J Transl Med       Date:  2011-12-08       Impact factor: 5.531

5.  Patterns of metastasis in women with metachronous contralateral breast cancer.

Authors:  V Vichapat; H Garmo; L Holmberg; I S Fentiman; A Tutt; C Gillett; M Lüchtenborg
Journal:  Br J Cancer       Date:  2012-06-26       Impact factor: 7.640

Review 6.  Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.

Authors:  N N Basu; L Barr; G L Ross; D G Evans
Journal:  Int J Surg Oncol       Date:  2015-01-27

7.  Prediction and clinical utility of a contralateral breast cancer risk model.

Authors:  Daniele Giardiello; Ewout W Steyerberg; Michael Hauptmann; Muriel A Adank; Delal Akdeniz; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Mariël Brinkhuis; Jenny Chang-Claude; Kamila Czene; Peter Devilee; Alison M Dunning; Douglas F Easton; Diana M Eccles; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Montserrat García-Closas; Lothar Haeberle; Christopher A Haiman; Per Hall; Ute Hamann; John L Hopper; Agnes Jager; Anna Jakubowska; Audrey Jung; Renske Keeman; Iris Kramer; Diether Lambrechts; Loic Le Marchand; Annika Lindblom; Jan Lubiński; Mehdi Manoochehri; Luigi Mariani; Heli Nevanlinna; Hester S A Oldenburg; Saskia Pelders; Paul D P Pharoah; Mitul Shah; Sabine Siesling; Vincent T H B M Smit; Melissa C Southey; William J Tapper; Rob A E M Tollenaar; Alexandra J van den Broek; Carolien H M van Deurzen; Flora E van Leeuwen; Chantal van Ongeval; Laura J Van't Veer; Qin Wang; Camilla Wendt; Pieter J Westenend; Maartje J Hooning; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2019-12-17       Impact factor: 6.466

8.  Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.

Authors:  Sara Alkner; Man-Hung Eric Tang; Christian Brueffer; Malin Dahlgren; Yilun Chen; Eleonor Olsson; Christof Winter; Sara Baker; Anna Ehinger; Lisa Rydén; Lao H Saal; Mårten Fernö; Sofia K Gruvberger-Saal
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

9.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

Authors:  Kerstin Rhiem; Christoph Engel; Monika Graeser; Silke Zachariae; Karin Kast; Marion Kiechle; Nina Ditsch; Wolfgang Janni; Christoph Mundhenke; Michael Golatta; Dominic Varga; Sabine Preisler-Adams; Tilman Heinrich; Ulrich Bick; Dorothea Gadzicki; Susanne Briest; Alfons Meindl; Rita K Schmutzler
Journal:  Breast Cancer Res       Date:  2012-12-07       Impact factor: 6.466

10.  Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.

Authors:  Anne S Reiner; Charles F Lynch; Julia S Sisti; Esther M John; Jennifer D Brooks; Leslie Bernstein; Julia A Knight; Li Hsu; Patrick Concannon; Lene Mellemkjær; Marc Tischkowitz; Robert W Haile; Ronglai Shen; Kathleen E Malone; Meghan Woods; Xiaolin Liang; Monica Morrow; Jonine L Bernstein
Journal:  Breast Cancer Res       Date:  2017-07-19       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.